Brigatinib is another treatment option for patients diagnosed with advanced ALK-positive non-small-cell lung cancer who are treatment-naïve or who have progressed on or are intolerant to crizotinib

Lignende værker

• Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib
  af: Jain, Rohit K, et al.
  Udgivet: (2017)
• Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
  af: Camidge, D. Ross, et al.
  Udgivet: (2020)
• Comparative analysis of alectinib and brigatinib in real-world treatment of advanced NSCLC with ALK rearrangements
  af: Kyuhwan Kim, et al.
  Udgivet: (2025-02-01)
• Real‐world evidence of brigatinib as second‐line treatment after crizotinib for ALK+ non‐small cell lung cancer using South Korean claims data (K‐AREAL)
  af: Jeong Eun Lee, et al.
  Udgivet: (2024-07-01)
• Lorlatinib Salvages CNS Relapse in ALK-Positive Non-Small-Cell Lung Cancer Patient Previously Treated with Crizotinib and High-Dose Brigatinib
  af: Sakamoto, MR, et al.
  Udgivet: (2018)